Related Experiment Videos
Activity of FCE 22101 against methicillin-resistant Staphylococcus aureus and affinity for penicillin binding
L J Piddock1, E A Traynor, R Wise
1Department of Medical Microbiology, Medical School, University of Birmingham, UK.
Abstract:
The susceptibility of 47 clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) to FCE 22101, imipenem and methicillin was determined with Iso-Sensitest media, with or without NaCl and with incubation at 30 degrees and 37 degrees C and for 24 and 48 h. All strains had a MIC 8 mg/l of methicillin under at least one of the culture conditions. The MIC90 of FCE 22101 was 1 mg/l, and that of imipenem 16 mg/l. The affinity of FCE 22101 for the penicillin-binding proteins (PBPs) of five clinical isolates of MRSA and S. aureus 13136 p-m+ was examined in envelope preparations and whole cell assay under the growth conditions listed above. PBP 2' was detected in all MRSA, and the clinical isolates had an I50 of 4 mg/l FCE 22101. These in-vitro data suggest that FCE 22101 may be active against MRSA in clinical use.
Insights
FCE 22101 shows promise against methicillin-resistant Staphylococcus aureus (MRSA). This novel antibiotic demonstrated potent in-vitro activity, suggesting potential clinical efficacy in treating MRSA infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant global health threat due to its resistance to conventional antibiotics.
- The development of new antimicrobial agents effective against MRSA is crucial for combating resistant infections.
Purpose of the Study:
- To evaluate the in-vitro susceptibility of clinical MRSA isolates to FCE 22101, imipenem, and methicillin.
- To investigate the mechanism of action of FCE 22101 by examining its affinity for penicillin-binding proteins (PBPs) in MRSA.
Main Methods:
- Susceptibility testing of 47 MRSA clinical isolates using Iso-Sensitest media under various conditions (NaCl presence, incubation temperatures, and durations).
- Determination of Minimum Inhibitory Concentrations (MICs) for FCE 22101, imipenem, and methicillin.
- Assay of FCE 22101 affinity for penicillin-binding proteins (PBPs), including PBP 2', in MRSA isolates.
Main Results:
- All tested MRSA strains exhibited resistance to methicillin under at least one tested condition.
- FCE 22101 demonstrated a potent MIC90 of 1 mg/l, significantly lower than imipenem (16 mg/l).
- FCE 22101 showed good affinity for PBP 2', a key protein in MRSA resistance, with an I50 of 4 mg/l.
Conclusions:
- FCE 22101 exhibits significant in-vitro activity against a range of MRSA clinical isolates.
- The drug's affinity for PBP 2' suggests a potential mechanism for its efficacy against MRSA.
- These findings support the potential clinical utility of FCE 22101 for treating MRSA infections.